Summary
Abbott Laboratories' 2011 10-K filing highlights a year of significant strategic moves and operational performance. The company announced its intention to separate into two independent publicly traded companies: one focused on diversified medical products (retaining the Abbott name) and the other on research-based pharmaceuticals. This strategic maneuver is expected to unlock value and allow each entity to better focus on its respective growth opportunities. Financially, Abbott demonstrated robust sales growth, driven by its Proprietary Pharmaceutical Products segment, particularly the strong performance of Humira. The company also benefited from strategic acquisitions, including Solvay Pharmaceuticals and Piramal Healthcare Limited's Healthcare Solutions business, which expanded its global reach and product portfolio, especially in emerging markets. Despite facing challenges such as patent expirations for certain products and increased generic competition, Abbott's diversified business model, strong product pipeline, and ongoing investment in research and development position it for continued growth.
Financial Highlights
56 data points| Revenue | $21.41B |
| Cost of Revenue | $10.02B |
| Gross Profit | $11.39B |
| SG&A Expenses | $7.37B |
| Operating Expenses | $19.78B |
| Operating Income | $1.63B |
| Interest Expense | $359.00M |
| Net Income | $4.71B |
| EPS (Basic) | $3.03 |
| EPS (Diluted) | $3.01 |
| Shares Outstanding (Basic) | 1.56B |
| Shares Outstanding (Diluted) | 1.57B |
Key Highlights
- 1Abbott announced plans to split into two publicly traded companies by the end of 2012: one for diversified medical products and one for research-based pharmaceuticals.
- 2Humira continued to be a significant revenue driver, with worldwide sales reaching $7.9 billion in 2011, representing a 19% increase from 2010.
- 3The company completed strategic acquisitions of Solvay Pharmaceuticals and Piramal Healthcare Limited's Healthcare Solutions business, bolstering its global presence and product offerings.
- 4Sales in the Proprietary Pharmaceutical Products segment increased by 11.0% in 2011, largely driven by Humira and growth in international markets.
- 5Research and development expenses increased by 10.9% to $4.1 billion in 2011, reflecting continued investment in new product development across key therapeutic areas.
- 6The company recorded a significant litigation charge of $1.5 billion related to ongoing settlement discussions in the U.S. government's investigation into Depakote sales and marketing activities.
- 7Abbott maintained strong financial health with net sales of $38.9 billion and net earnings of $4.7 billion in 2011.